Xeris Biopharma Holdings
XERS
144 hedge funds and large institutions have $182M invested in Xeris Biopharma Holdings in 2024 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 48 increasing their positions, 34 reducing their positions, and 14 closing their positions.
271% more call options, than puts
Call options by funds: $1.26M | Put options by funds: $340K
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
41% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 34
33% more capital invested
Capital invested by funds: $136M → $182M (+$45.7M)
7% more funds holding
Funds holding: 134 → 144 (+10)
1.99% more ownership
Funds ownership: 40.91% → 42.9% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$5.61M |
| 2 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
+$5.18M |
| 3 |
Walleye Capital
New York
|
+$2.88M |
| 4 |
Morgan Stanley
New York
|
+$1.91M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$10.9M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.49M |
| 3 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$1.33M |
| 4 |
Lazard Asset Management
New York
|
-$662K |
| 5 |
Millennium Management
New York
|
-$644K |
XERS Hedge Fund Activity: Q3 2024 in Review
144 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q3 2024, worth a combined $182M — up 33% from $136M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new XERS positions and 14 closed out — a net gain of 11 holders — while 48 added to existing stakes and 34 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $5.61M. The largest seller was MPM BioImpact, exiting entirely with an estimated $10.9M sold.
- 144 institutional investors held Xeris Biopharma Holdings (XERS) as of Q3 2024, up from 134 in Q2 2024.
- Funds reported $182M of Xeris Biopharma Holdings stock for Q3 2024, up 33% quarter-over-quarter.
- 25 funds opened new Xeris Biopharma Holdings positions in Q3 2024 and 14 closed out, a net change of +11 holders.
- The largest Xeris Biopharma Holdings buyer in Q3 2024 was AIGH Capital Management, an estimated $5.61M added.
- The largest Xeris Biopharma Holdings seller in Q3 2024 was MPM BioImpact, an estimated $10.9M sold.
Based on aggregated 13F filings for Q3 2024.